GET DAILY SIGNALSIXJ vs XLV: Weighing Global Healthcare Diversification Against Concentrated U.S. Exposure
Key Takeaways
- IXJ offers globally diversified healthcare exposure across roughly 140 holdings in the United States and developed international markets, while XLV concentrates on about 60 U.S. large-cap names from the S&P 500.
- Cost efficiency strongly favors XLV, whose expense ratio of approximately 0.08% is a fraction of IXJ's roughly 0.38%–0.40%.
- XLV carries a materially higher concentration in a few mega-cap leaders, with Eli Lilly near 15%–16% of assets, amplifying single-stock risk versus IXJ's more balanced weighting.
- IXJ adds geographic diversification and broader sub-industry exposure, including meaningful weightings in Swiss, British, Japanese, and Danish pharmaceutical champions.
- Both funds are passively managed, market-capitalization-weighted vehicles with similar defensive characteristics, making the choice primarily one of geographic scope, concentration, and cost.
- Tickeron AI Verdict: XLV is the favored ticker, reflecting its lower cost, deeper liquidity, and concentrated exposure to high-momentum U.S. healthcare leaders.
Why These Two Healthcare ETFs Stand Out
Healthcare remains one of the most durable and economically resilient sectors in the equity market, combining defensive cash-flow characteristics with secular growth drivers such as aging demographics, pharmaceutical innovation, and medical-device advancement. The iShares Global Healthcare ETF (IXJ) and the Health Care Select Sector SPDR Fund (XLV) are two of the most widely used passive vehicles for accessing this space, yet they are not direct substitutes. IXJ casts a global net across developed markets, while XLV focuses exclusively on U.S. large-cap constituents of the S&P 500. For investors weighing an ETF comparison of sector exposure and relative positioning, understanding these structural differences is essential to selecting the tool that best matches a given investment objective. I also checked this using Tickeron’s AI Screener to see how the funds compare to others in the industry.
A Closer Look at IXJ
IXJ is a passively managed fund that seeks to track the S&P Global 1200 Health Care (Sector) Capped Index, a market-capitalization-weighted benchmark of large-capitalization healthcare companies across major global markets. The fund holds roughly 140 securities, providing exposure to pharmaceutical, biotechnology, and medical-device companies worldwide. Although the United States dominates at approximately 70%–74% of assets, IXJ also allocates meaningfully to Switzerland, the United Kingdom, Japan, Denmark, and France, distinguishing it from domestic-only funds.
Top holdings include LLY, JNJ, ABBV, MRK, and UNH, alongside non-U.S. leaders such as Roche Holding, Novartis, and AstraZeneca. By industry, pharmaceuticals represent the largest weighting (roughly 42%), followed by health care equipment and supplies, biotechnology, and providers and services. The fund carries an expense ratio of approximately 0.38%–0.40% and has traded since its 2001 launch, offering broad, lower-concentration diversification within the healthcare universe.
A Closer Look at XLV
XLV is a passively managed fund that seeks to replicate the Health Care Select Sector Index, which comprises healthcare companies drawn from the S&P 500. The fund is non-diversified and market-capitalization-weighted, holding approximately 60 to 64 U.S. large-cap names. Its low expense ratio of roughly 0.08% makes it among the least expensive healthcare ETFs available, and its sizeable asset base supports tight bid-ask spreads and deep secondary-market liquidity.
Concentration is a defining feature: the top 10 holdings account for roughly 60% of assets, led by LLY (approximately 15%–16%), JNJ, ABBV, UNH, and MRK, with additional weight in TMO, AMGN, and GILD. By industry, health care equipment and supplies is the largest segment (near 37%), with pharmaceuticals, providers and services, and life sciences tools each contributing meaningfully. Launched in 1998, XLV is the largest broad healthcare ETF by assets.
Current Industry and Thematic Context
The healthcare sector continues to attract investor capital through a mix of defensive stability and innovation-driven growth. Blockbuster categories such as GLP-1 weight-loss and diabetes therapies have reshaped the pharmaceutical landscape, benefiting heavyweight holdings like Eli Lilly and Novo Nordisk. Meanwhile, medical-device and life-sciences companies are supported by recovering procedure volumes and hospital capital spending.
Macro conditions also play a role. Healthcare is generally less sensitive to interest-rate cycles than other sectors, which has supported its appeal during periods of monetary-policy uncertainty. However, the sector carries structural risks, including U.S. drug-pricing legislation, regulatory scrutiny of insurers and pharmacy benefit managers, and patent-expiration cliffs for certain large pharmaceutical franchises. For global funds such as IXJ, currency movements and foreign regulatory environments add another layer of complexity that domestic-only XLV avoids.
Performance and Positioning Comparison
In recent weeks and across recent market cycles, both funds have generally tracked the broader healthcare complex, but their differing compositions have produced distinct fund performance profiles. XLV's heavier tilt toward Eli Lilly and other U.S. mega-cap pharmaceutical leaders has allowed it to capture more upside during periods when weight-loss and innovation narratives dominate, though this concentration also raises single-stock sensitivity. IXJ's broader, globally diversified portfolio has historically exhibited lower drawdowns and a more balanced return stream, with its international holdings providing exposure to European and Japanese healthcare champions not present in XLV.
From a relative positioning standpoint, XLV benefits from lower cost and superior liquidity, while IXJ offers superior diversification and reduced idiosyncratic risk. Both remain defensive relative to the broad market, with equity beta generally below that of the broader index.
Using Tickeron AI Tools in My Research
I often turn to Tickeron’s AI tools when comparing sector ETFs like these. The platform’s pattern recognition and trend signals help me quickly assess how holdings align with current momentum, and I’ve found the AI Daily Buy/Sell Signals particularly useful for spotting shifts in healthcare names. From what I see, these resources complement traditional analysis without replacing it.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
Aroon Indicator for IXJ shows an upward move is likely
IXJ's Aroon Indicator triggered a bullish signal on November 06, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 263 similar instances where the Aroon Indicator showed a similar pattern. In 218 of the 263 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on IXJ as a result. In 70 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for IXJ just turned positive on October 12, 2026. Looking at past instances where IXJ's MACD turned positive, the stock continued to rise in 40 of 49 cases over the following month. The odds of a continued upward trend are 82%.
IXJ moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for IXJ crossed bullishly above the 50-day moving average on October 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +3.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where IXJ advanced for three days, in 256 of 319 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The 10-day RSI Indicator for IXJ moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 29 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 81%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 68 cases where IXJ's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 72%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IXJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
IXJ broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Category Health
Advertisement